CONSOLIDATED BALANCE SHEETS (USD $) In Millions, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$ 808.8	$ 600.3
Trade receivables, net	1,880.2	1,676.4
Inventories, net	932.7	883.0
Prepaid expenses and other current assets	465.6	343.4
Assets held for sale	10.0	15.9
Deferred tax assets, net	316.4	366.9
Total current assets	4,413.7	3,885.9
Property, plant and equipment, net	1,300.4	1,234.2
Intangible assets, net	11,620.4	12,848.2
Goodwill	9,467.8	9,752.1
Deferred tax assets, net	23.9	54.9
Other long-term assets, net	233.4	195.5
Total assets	27,059.6	27,970.8
Current liabilities:
Accounts payable	323.3	327.0
Accrued and other current liabilities	1,993.9	1,800.2
Acquisition-related contingent consideration	116.5	114.5
Current portion of long-term debt	690.6	204.8
Deferred tax liabilities, net	19.0	66.0
Total current liabilities	3,143.3	2,512.5
Acquisition-related contingent consideration	211.3	241.3
Long-term debt	15,584.3	17,162.9
Pension and other benefit liabilities	157.7	172.0
Liabilities for uncertain tax positions	113.8	169.1
Deferred tax liabilities, net	2,407.0	2,319.2
Other long-term liabilities	208.6	160.5
Total liabilities	21,826.0	22,737.5
Equity
Common shares, no par value, unlimited shares authorized, 334,004,879 and 333,036,637 issued and outstanding at September 30, 2014 and December 31, 2013, respectively	8,334.4	8,301.2
Additional paid-in capital	240.2	228.8
Accumulated deficit	(2,899.9)	(3,278.5)
Accumulated other comprehensive loss	(552.0)	(132.8)
Total Valeant Pharmaceuticals International, Inc. shareholders’ equity	5,122.7	5,118.7
Noncontrolling interest	110.9	114.6
Total equity	5,233.6	5,233.3
Total liabilities and equity	$ 27,059.6	$ 27,970.8